With interest in psychedelic drugs clearly back on the public's radar, policymakers should act now to take measures that would avoid a repeat of mistakes made during the mass commercialization of cannabis, a new report suggests.
No takes yet. Share an insight, caveat, or question.
Gary Enos (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: